stockrowBioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
- Revenue
- +32.0%
- EPS
- −296.6%
- Free cash flow
- −52.3%
- Total debt
- +599.5%
Quarter to September 2026, against a year earlier
Follow BMRN
Alert me
BioMarin Pharmaceutical Inc. (BMRN) EBITDA
BioMarin Pharmaceutical Inc.'s EBITDA for fiscal 2025 was $484.2M, down 15.4% from $572.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was $374.0M. Over the past ten years it has ranged from −$705.2M (fiscal 2016) to $572.3M (fiscal 2024); the current reading is higher than 91% of that period. BioMarin Pharmaceutical Inc. ranks 12th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $484.2M | (15.39%) |
| FY2024 | $572.3M | 103.71% |
| FY2023 | $280.9M | 5.62% |
| FY2022 | $266.0M | 762.11% |
| FY2021 | $30.9M | (50.48%) |
| FY2020 | $62.3M | 2,091.39% |
| FY2019 | $2.8M | — |
| FY2018 | −$27.5M | — |
| FY2017 | $76.2M | — |
| FY2016 | −$705.2M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $48.4M | (76.85%) |
| Jun 2026 | $209.0M | 43.56% |
| Mar 2026 | $145.6M | — |
| Dec 2025 | −$29.0M | — |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. | $374.0M |
| TECH Bio-Techne Corp compare | $349.2M |
| CAI Caris Life Sciences,�Inc. compare | $180.0M |
| TGTX TG Therapeutics, Inc. compare | $136.0M |
| TWST Twist Bioscience Corporation compare | −$119.6M |
| IBRX ImmunityBio, Inc. compare | −$235.2M |
| KYMR Kymera Therapeutics, Inc. compare | −$405.5M |
| SMMT Summit Therapeutics PLC compare | −$872.8M |
| PCVX Vaxcyte, Inc. compare | −$1.1B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on BMRN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement